Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,213.7
-

 

  • STI Straits Times Index
    3,213.7
    -
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,663.7
    -20.6 (-1.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,071.6
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,101.5
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,681.0
    72.0 (0.33%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,501.8
    -
    Index delayed 10 minutes
  • KOR KOSPI
    2,193.5
    8.6 (0.39%)
    Index delayed 20 minutes
  • XAO XAO
    6,307.6
    54.1 (0.87%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 706.8M
  • Value: 915.8M
  • Rise: 156
  • Fall: 137
  • Unch: 553

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Kep Infra Tr0.470-
Ascendas Reit2.860-
SGX7.410-
UOB25.210-
UMS0.760-
3Cnergy0.009-
800 Super0.670-
8Telecom^0.058-
A-Smart0.420-
A-Sonic Aero^0.230-

World Indices

World Indices
Name Last Change
Nasdaq 7,839.0 +110.0
HSI 29,071.6
HSCEI 11,544.1
Jakarta 6,501.8
Nikkei 225 21,628.9 +20.0
SSE Comp 3,101.5
Shanghai A 3,248.4
Shanghai B 307.6
ShenZhen A 1,775.3
ShenZhen B 1,034.8
Taiwan W 10,609.5
PSE Comp 0.0
KOSPI 2,192.3 +7.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 22 Mar 2019 08:47
Last (SGD): 0.210 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.210
Buy Price 0.210 Sell Price 0.220
Buy Volume ('000) 100.0 Sell Volume ('000) 20.0
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.01803 Trailing EPS (SGD) e 0.01803 NAV (SGD) b 0.1305
PE a 11.647 Trailing PE f 11.645 Price / NAV b 1.6092
Dividend (SGD) d 0.005500 Cash In Hand (SGD) g 0.0745 Issued & Paid-up Shares c 300,000,000
Dividend Yield (%) d 2.619 Price / Cash In Hand g 2.819 Treasury Shares h -
Beta - 75 Daysi 0.213 R-Squared - 75 Days(%)i 0.20 Market Cap (M) 63.000
Beta - 500 Daysi 0.298 R-Squared - 500 Days (%)i 0.79 Enterprise Value (M) 43.647
Piotroski F Score - Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 6-Month VWAP 0.211 Free Float (%) 20.0
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Commerce - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 04 Mar 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 63.000 11.647 11.645 1.6092 2.619
Industry Medical & Biotechnology SGX 1,054.126 23.565 23.435 1.4397 1.792
Pharmaceuticals: Major SGX 34.941 9.539 9.539 1.0317 2.361
Local Peer Star Pharm^ SGX 6.881 3.591 3.591 0.2408 -
Global Peer JOHNSON & JOHNSON NYSE 367,728.537 24.039 24.039 6.1542 2.563
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 238,892.006 18.900 18.900 3.0388 1.782
Global Peer PFIZER INC NYSE 235,118.730 21.083 21.083 3.7092 3.356
Global Peer MERCK & CO INC NYSE 214,112.199 34.423 34.423 8.0189 2.410
Global Peer ELI LILLY AND COMPANY NYSE 132,854.740 41.106 41.106 13.5170 1.790
Global Peer ABBVIE INC NYSE 119,835.499 21.184 21.184 -14.1884 4.874
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 108,662.212 50.509 50.509 8.7153 3.195
Global Peer NOVO-NORDISK AS ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 104,995.255 17.172 17.172 13.2217 2.037
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 102,376.650 21.192 21.192 18.4362 4.959
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 79,860.432 16.232 16.232 5.6917 3.274
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), CHINARES PHARMA (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), INNOVENT BIO-B (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), HUTCHISON CHINA MEDITECH SPON ADR EACH REPR 0.50 ORD SHS (NASDAQ), JUNSHI BIO-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), CMS (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CHINAGRANDPHARM (HKEx), CSTONE PHARMA-B (HKEx), ALLAKOS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), GOSSAMER BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), TRICIDA INC (NASDAQ), RA PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE-B (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), CLEMENTIA PHARMACEUTICALS INC (NASDAQ), UNITED LAB (HKEx), PRINCIPIA BIOPHARMA INC (NASDAQ), PETIQ INC (NASDAQ), NIGHTSTAR THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), EVOLUS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), ODONATE THERAPEUTICS LLC (NASDAQ), FORTY SEVEN INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), QUANTERIX CORPORATION (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), ZYMEWORKS INC (NYSE), TCR2 THERAPEUTICS INC (NASDAQ), AKORN INC (NASDAQ), IGBB (Bursa), BEYONDSPRING INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NC HEALTHCARE (HKEx), UROVANT SCIENCES LTD (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), FUSEN PHARM (HKEx), KRYSTAL BIOTECH INC (NASDAQ), AC IMMUNE SA (NASDAQ), LANNETT CO INC (NYSE), VERRICA PHARMACEUTICALS INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), DAWNRAYS PHARMA (HKEx), GAMIDA CELL LTD (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), DOVA PHARMACEUTICALS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), Merck Tbk. (IDX), SOL GEL TECHNOLOGIES LTD (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CHARMACY PHAR (HKEx), PROVENTION BIO INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), SIENNA BIOPHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), TELIGENT INC NEW (NASDAQ), NEP INTERLONG (HKEx), EYENOVIA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), KOTRA (Bursa), ARCTURUS THERAPEUTICS LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TPI ENTERPRISES LIMITED (ASX), MEDLAB CLINICAL LIMITED (ASX), HOTH THERAPEUTICS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ENTERA BIO LTD (NASDAQ), BIOHLDG (Bursa), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), MMJ GROUP HOLDINGS LTD (ASX), NOVUS THERAPEUTICS INC (NASDAQ), SINOLIFE UTD (HKEx), MOLECULIN BIOTECH INC (NASDAQ), NOVA (Bursa), NOVAN INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), NOXOPHARM LTD (ASX), AILERON THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), EXOPHARM LTD (ASX), CITIUS PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), ESSA PHARMA INC (NASDAQ), GEMPHIRE THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), FARMAFORCE LTD (ASX), RACE ONCOLOGY LTD (ASX), FIJI KAVA LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.005
+2.44 %
10 Days --0.015
-6.67 %
20 Days -+0.039
+22.81 %
Medium Term Return 3 Months -+0.020
+10.53 %
6 Months -+0.010
+5.00 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.160 - 0.305 Change From 1 Year Low +0.050 % Change From 1 Year Low (%) +31.25
Change From 1 Year High -0.095 % Change From 1 Year High (%) -31.15
2 Years Range 0.160 - 0.305 Change From 2 Years Low +0.050 % Change From 2 Years Low (%) +31.25
Change From 2 Years High -0.095 % Change From 2 Years High (%) -31.15
5 Years Range 0.160 - 0.305 Change From 5 Years Low +0.050 % Change From 5 Years Low (%) +31.25
Change From 5 Years High -0.095 % Change From 5 Years High (%) -31.15
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapore’s leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.

The Group’s core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) -19.23 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
21 Mar 2019 0.210 0.210 0.210 0.210 - -
20 Mar 2019 0.210 0.210 0.210 0.210 - -
19 Mar 2019 0.210 0.210 0.210 0.210 20,000 0.2100
18 Mar 2019 0.210 0.210 0.210 0.210 105,000 0.2100
15 Mar 2019 0.210 0.215 0.200 0.210 144,800 0.2076
14 Mar 2019 0.205 0.210 0.205 0.205 75,000 0.2057
13 Mar 2019 0.205 0.205 0.205 0.205 3,000 0.2050
12 Mar 2019 0.220 0.220 0.220 0.220 5,900 0.2200
11 Mar 2019 0.225 0.225 0.220 0.220 20,000 0.2225
08 Mar 2019 0.225 0.230 0.225 0.225 256,600 0.2281
07 Mar 2019 0.225 0.240 0.225 0.225 815,900 0.2286
06 Mar 2019 0.225 0.225 0.215 0.220 63,300 0.2208
05 Mar 2019 0.200 0.230 0.200 0.220 171,700 0.2093
04 Mar 2019 0.194 0.194 0.194 0.194 - -
01 Mar 2019 0.194 0.194 0.194 0.194 10,000 0.1940
28 Feb 2019 0.176 0.176 0.176 0.176 - -
27 Feb 2019 0.176 0.176 0.176 0.176 - -
26 Feb 2019 0.176 0.176 0.176 0.176 - -
25 Feb 2019 0.176 0.176 0.176 0.176 - -
22 Feb 2019 0.176 0.176 0.176 0.176 7,000 0.1760
21 Feb 2019 0.171 0.171 0.171 0.171 - -
20 Feb 2019 0.171 0.171 0.171 0.171 - -
Summary
Current 2 Weeks
(08 Mar 2019 to 21 Mar 2019)
0.225 0.230 0.200 0.210 630,300 -
Previous 2 Weeks
(22 Feb 2019 to 07 Mar 2019)
0.176 0.230 0.176 0.225 1,067,900 -
4 Weeks from
(23 Jan 2019 to 21 Feb 2019)
0.185 0.230 0.185 0.171 279,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.